Skip Navigation

COVID-19 Update

Find a Doctor

Find a Researcher


Amita Gupta, M.D.

Photo of Dr. Amita Gupta, M.D.
  • Deputy Director, Johns Hopkins University Center for Clinical Global Health Education
  • Professor of Medicine

Languages: English, French, Hindi, Spanish


HIV/AIDS, Infectious Disease, Infectious Diseases, Tuberculosis

Research Interests

HIV and co-infection care and treatment clinical trials in India and other resource-constrained countries; Mother-to-child transmission prevention; Diarrheal diseases epidemiology; Malnutrition and TB-HIV coinfection in adults and children more


The Johns Hopkins Hospital

600 N. Wolfe Street
Outpatient Moore Clinic, Suite 384
Baltimore, MD 21287 map
Phone: 410-502-7696


Dr. Gupta is Deputy Director of the Johns Hopkins (JH) Center for Clinical Global Health Education (CCGHE), and Associate Professor of Infectious Diseases at the JH School of Medicine, with a joint appointment in International Health at the JH Bloomberg School of Public Health.

Board certified by the American Board of Internal Medicine in infectious diseases, Dr. Gupta specializes in international public health, clinical research, and education in infectious diseases, HIV/AIDS, and tuberculosis (TB). Since 2002, her work has been focused primarily on India, where she leads several Indo-JHU research collaborations, including the C-TRIUMPH and RePORT consortium for tuberculosis (TB) research funded by the US National Institutes of Health (NIH) and the government of India. Dr. Gupta is also Co-principal Investigator of the NIH-funded Baltimore-Washington-India (BWI) HIV and Infectious Diseases Clinical Trials Unit (CTU), and she is an active clinical investigator in multi-country HIV/TB trials conducted by the AIDS Clinical Trials Group (ACTG) and the International Maternal Pediatric Adolescent AIDS Trials Network (IMPAACT). Additionally, she has been awarded research grants from the NIH, CDC, and several philanthropic foundations to investigate TB in children and pregnant women, malnutrition, infection and inflammation, HIV treatment outcomes, and antibiotic resistance.

Dr. Gupta is an author of more than 90 peer-reviewed research publications and 7 book chapters, primarily on prevention and treatment of HIV, TB, and other infectious diseases, predominantly in low- and middle-income settings. She has also mentored more than 30 junior scientists in India and the US to run research studies and submit their own scientific findings to peer-reviewed publications.

From 2000–2002, Dr. Gupta worked for the US Centers for Disease Control and Prevention (CDC), where she was engaged in global public health projects in the US, Guatemala, Vietnam, and Micronesia.

Dr. Gupta received an undergraduate degree from MIT, a Doctor of Medicine from Harvard Medical School, and a Master of Health Sciences in clinical investigation from JH Bloomberg School of Public Health. She completed her internal medicine training at San Francisco General Hospital-University of California, San Francisco, followed by a post-doctoral fellowships with the Epidemic Intelligence Service at the US Centers for Disease Control and Prevention and at the JHU School of Medicine. more


  • Deputy Director, Johns Hopkins University Center for Clinical Global Health Education
  • Professor of Medicine

Departments / Divisions

Centers & Institutes



  • MD, Harvard Medical School (1997)


  • University of California San Francisco School of Medicine / Internal Medicine (2000)


  • Centers for Disease Control and Prevention / Epidemiology (2002)
  • Johns Hopkins University School of Medicine / Infectious Diseases (2005)

Research & Publications

Lab Website: Amita Gupta Lab

Clinical Trial Keywords

tuberculosis, HIV, PMTCT, breastfeeding, antiretroviral, MDR-TB

Clinical Trials

ACTG 5273: Multicenter Study of Options for Second-Line Effective Combination Therapy (SELECT)

ACTG 5274: Phase IV, Open Label Strategy Trial: REMEMBER: Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens

ACTG 5282: A Randomized, Phase II Trial to Compare an HPV Test-and-Treat Strategy to a Cytology-Based Strategy for Prevention of CIN 2+ in HIV-Infected Women 

ACTG 5288: Management Using the Latest Technologies in Resource-limited Settings to Optimize Combination Therapy After Viral Failure

ACTG 5300/IMPAACT 2003: Phase III, Open Label, Multi-center Trial: Protecting Households on Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients

IMPAACT 1026: Pharmacokinetic Properties of Antiretroviral Drugs During Pregnancy

IMPAACT 1077B/1077FF: Promoting Maternal and Infant Survival Everywhere (PROMISE): Breastfeeding and Formula Feeding Versions

IMPAACT 1078: Phase IV Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety of Immediate (Antepartum-Initiated) Versus Deferred (Postpartum-Initiated) Isoniazid Preventive Therapy Among HIV-Infected Women in High TB Incidence Settings

Selected Publications

Nishi Suryavanshi; Vidya Mave; Nikhil Gupte; Ramesh Bhosale; Pradeep Sambarey; Sandesh Patil; Jayagowri Sastry; Robert Bollinger; Amita Gupta; Anita Shankar. "Contraceptive use and factors associated with postpartum surgical sterilization among HIV-infected women in Pune, India." Journal of HIV/AIDS and Social Services. 2015;14(3):359-370.

Mave V, Chandanwale A, Bhosale R, Shere D, Gupte N, Suryavanshi N, Kulkarni V, Kagal A, Bharadwaj R, Joshi S, Bollinger RC, Gupta A; SWEN (Six Weeks Extended Nevirapine India) and Byramjee-Jeejeebhoy Medical College Clinical Trials Unit Study team. "Vitamin D deficiency and risk of postpartum tuberculosis among HIV-infected breastfeeding mothers in India." Int J Tuberc Lung Dis. 2015 Mar;19(3):302-4. doi: 10.5588/ijtld.14.0658.

Tenforde MW, Gupte N, Dowdy DW, Asmuth DM, Balagopal A, Pollard RB, Sugandhavesa P, Lama JR, Pillay S, Cardoso SW, Pawar J, Santos B, Riviere C, Mwelase N, Kanyama C, Kumwenda J, Hakim JG, Kumarasamy N, Bollinger R, Semba RD, Campbell TB, Gupta A; ACTG PEARLS and NWCS 319 Study Group. "C-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settings." PLoS One. 2015 Feb 26;10(2):e0117424. doi: 10.1371/journal.pone.0117424. eCollection 2015.

Havers FP, Detrick B, Cardoso SW, Berendes S, Lama JR, Sugandhavesa P, Mwelase NH, Campbell TB, Gupta A; ACTG A5175 PEARLS and NWCS319 Study Teams. "Change in vitamin D levels occurs early after antiretroviral therapy initiation and depends on treatment regimen in resource-limited settings." PLoS One. 2014 Apr 21;9(4):e95164. doi: 10.1371/journal.pone.0095164. eCollection 2014.

Gupta A, Mathad JS, Yang WT, Singh HK, Gupte N, Mave V, Bharadwaj R, Zaman K, Roy E, Bollinger RC, Bhosale R, Steinhoff MC. "Maternal pneumococcal capsular IgG antibodies and transplacental transfer are low in South Asian HIV-infected mother-infant pairs." Vaccine. 2014 Mar 14;32(13):1466-72. doi: 10.1016/j.vaccine.2014.01.033. Epub 2014 Jan 30.

Savic R, Ruslami R, Hibma J, Hessling A, Ramachandran G, Gamiem AR, Swaminathan S, Mcilleron H, Gupta A, Thakur K, vanCrevel R, Aarnoutse R, Dooley K. Pediatric tuberculous meningitis: model-based approach to determining optimal does of anti-tuberculosis drugs for children. Clin Pharmacol Ther. 2015 Oct 22. doi:10.1002/cpt.202. [Epub ahead of print]

Maddali MV, Dowdy DW, Gupta A, Shah M. Economic and epidemiological impact of early antiretroviral therapy initiation in India. Journal of the International AIDS Society. 2015;18:20217.

Balagopal A, Asmuth DM, Yang W-T, Campbell T, Gupte N, Smeaton L, Kanyama C, Grinsztejn B, Santos B, Supparatpinyo K, Badal-Faesen S, Lama JR, Lalloo U, Zulu F, Pawar JS, Riviere C, Kumarasamy N, Hakim J, Li X-D, Pollard RB, Semba RD, Thomas DL, Bollinger RC, Gupta A. Pre-cART elevation of CRP and CD4+ T-cell immune activation associated with HIV clinical progression in m Multinational case-cohort study. J Acquir Immune Def Syndr 2015 Oct 1.

Hamilton CD, Swaminathan S, Christopher DJ, Ellner J, Gupta A, Sterling TR, Rolla V, Srinivasan S, Karyana M, Siddiqui S, Stoszek SK, Kim P. RePORT International: advancing tuberculosis biomarker research through global collaboration. Clinical Infectious Diseases. 2015;61(suppl 3):S155-S159 doi: 10.1093/cid/civ611.

Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T, Supparatpinyo K, Mohapi L, Gupta A, Benson Cam, Kim P, Fletcher CV on behalf of the ACTG A5279 Study Team. Efavirenz pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis prevention. Clin Infect Dis. 2015;16 Jun. pii: civ464. [Epub ahead of print]

Gandhi BS, Kulkarni K, Godbole M, Dole SS, Kapur S, Satpathy P, Khatri AM, Deshpande PS, Azad F, Gupte N, Bharadwaj R, Bollinger RC, Gupta A. Dengue and chikungunya co-infection associated with more severe clinical disease than mono-infection. International J. of Healthcare and Biomedical Research. 2015 Apr;3(3)

Shivakoti R, Yang WT, Gupte N, Berendes S, Rose A, Cardoso SW, Mwelase N, Kanyama C, Pillay S, Samaneka W, Riviere C, Sugandhavesa P, Santos B, Poongulali S, Tripathy S, Bollinger RC, Currier JS, Tang AM, Semba RD, Christian P, Campbell TB, Gupta A; NWCS 319 and PEARLS Study Team. Concurrent anemia and elevated CRP predicts HIV clinical treatment failure, including TB, post-antiretroviral therapy initiation. Clin Infect Dis. 2015 Mar 31. doi: 10.1093/cid/civ265. [Epub ahead of print]

Academic Affiliations & Courses

Graduate Program Affiliation

International Health, Bloomberg School of Public Health

Activities & Honors


  • Infectious Diseases Society of America
  • American Medical Association
  • American Society of Tropical Medicine and Hygiene

Professional Activities

  • Vice Chair, IMPAACT TB Scientific Committee
  • Member, ACTG TB transformative Science Group
  • Co-Chair, NIH/Indian Government TB Research Consortium (RePORT)

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • ...Loading ratings...
  • ... 
  • ... 
  • ... 
  • ... 
  • ... 


Is this you? Edit Profile
back to top button